News

Higher exposure to outdoor light at night may increase the risk of developing Alzheimer’s disease, especially in people younger than 65, according to a study that drew on Medicare records and satellite-based light pollution maps. “Average nighttime light intensity was more strongly associated with [Alzheimer’s disease] prevalence than some…

After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing the oral therapy simufilam in people with Alzheimer’s disease. The board’s findings were announced by therapy developer…

September is awareness month for Alzheimer’s disease and other forms of dementia, and Alzheimer’s Disease International (ADI) is calling on the disease to be made a global health priority with the theme, “Time to act on dementia, time to act on Alzheimer’s.” Several initiatives have been held…

Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild to moderate Alzheimer’s disease who took part in a Phase 2/3 clinical trial, despite being safe and well tolerated, top-line data show. “These are not the results we hoped…

Fujirebio Diagnostics asked the U.S. Food and Drug Administration (FDA) to approve its Alzheimer’s disease diagnostic blood test,  Lumipulse G pTau 217/β [beta]-Amyloid 1-42 Plasma Ratio. If approved, the test would be the first commercially available blood-based in vitro test in the U.S. to aid in diagnosing…

Alzamend Neuro is partnering with Massachusetts General Hospital to conduct a Phase 2 clinical trial of AL001, an oral therapy being developed for dementia related to Alzheimer’s disease. The trial will compare the brain levels of AL001, a novel lithium-delivery system, with those of marketed lithium, in healthy…

Amylyx Pharmaceuticals‘ investigational oral therapy AMX0035 reduces the levels of several biomarkers associated with Alzheimer’s disease, according to an analysis of data from the PEGASUS trial. “The results from this exploratory analysis suggest that AMX0035 engages important pathways implicated in the [development] of Alzheimer’s disease and other neurodegenerative…

Treatment with CT1812, previously called Elayta, slowed the decline of cognitive function among adults with mild to moderate Alzheimer’s disease in a proof-of-concept clinical trial dubbed SHINE. That’s according to results seen after approximately six months of treatment in the Phase 2 SHINE study (NCT03507790) at…

Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study, the first and largest to focus on people who have early signs of Alzheimer’s disease but are not yet showing symptoms, are now available to researchers around the world. Recognizing a need for starting treatment before any symptoms appear,…

Nearly one year of treatment with blarcamesine (Anavex 2-73), a once-daily oral small molecule being developed by Anavex Life Sciences, slowed cognitive and functional decline in people with early Alzheimer’s disease, according to data from a global Phase 2b/3 clinical study. Researchers also observed that patients on…